Oregon Public Employees Retirement Fund Takes $1.29 Million Position in Amedisys Inc (AMED)

Oregon Public Employees Retirement Fund bought a new position in shares of Amedisys Inc (NASDAQ:AMED) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 11,036 shares of the health services provider’s stock, valued at approximately $1,292,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Amedisys by 14.3% in the third quarter. Vanguard Group Inc. now owns 3,326,180 shares of the health services provider’s stock valued at $415,640,000 after purchasing an additional 415,060 shares in the last quarter. Vanguard Group Inc raised its position in Amedisys by 14.3% during the third quarter. Vanguard Group Inc now owns 3,326,180 shares of the health services provider’s stock valued at $415,640,000 after purchasing an additional 415,060 shares in the last quarter. JPMorgan Chase & Co. raised its position in Amedisys by 14.6% during the third quarter. JPMorgan Chase & Co. now owns 934,137 shares of the health services provider’s stock valued at $116,731,000 after purchasing an additional 118,936 shares in the last quarter. Acadian Asset Management LLC raised its position in Amedisys by 218.9% during the third quarter. Acadian Asset Management LLC now owns 609,586 shares of the health services provider’s stock valued at $76,177,000 after purchasing an additional 418,424 shares in the last quarter. Finally, Alliancebernstein L.P. raised its position in Amedisys by 141.4% during the third quarter. Alliancebernstein L.P. now owns 396,533 shares of the health services provider’s stock valued at $49,551,000 after purchasing an additional 232,255 shares in the last quarter. 96.45% of the stock is currently owned by institutional investors.

AMED has been the subject of several research analyst reports. BidaskClub downgraded shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 16th. Craig Hallum downgraded shares of Amedisys from a “buy” rating to a “hold” rating and reduced their target price for the company from $116.00 to $104.00 in a research report on Friday, October 26th. Benchmark raised shares of Amedisys from a “hold” rating to a “buy” rating and set a $125.00 price objective for the company in a report on Tuesday, October 30th. UBS Group initiated coverage on shares of Amedisys in a report on Friday, November 16th. They issued a “neutral” rating and a $126.00 price objective for the company. Finally, ValuEngine raised shares of Amedisys from a “buy” rating to a “strong-buy” rating in a report on Wednesday, November 28th. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Amedisys currently has a consensus rating of “Buy” and an average target price of $114.62.

AMED traded down $0.49 on Tuesday, hitting $131.57. The company’s stock had a trading volume of 3,698 shares, compared to its average volume of 315,161. The company has a market cap of $4.21 billion, a PE ratio of 59.95, a price-to-earnings-growth ratio of 1.72 and a beta of 1.43. Amedisys Inc has a 12 month low of $54.06 and a 12 month high of $140.91. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.12.

In other news, insider David B. Pearce sold 410 shares of Amedisys stock in a transaction dated Monday, December 24th. The shares were sold at an average price of $106.61, for a total transaction of $43,710.10. Following the sale, the insider now owns 11,010 shares of the company’s stock, valued at approximately $1,173,776.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael Paul North sold 5,625 shares of Amedisys stock in a transaction dated Wednesday, November 14th. The shares were sold at an average price of $117.57, for a total transaction of $661,331.25. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,952 shares of company stock valued at $1,587,677. 2.60% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: “Oregon Public Employees Retirement Fund Takes $1.29 Million Position in Amedisys Inc (AMED)” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2019/02/12/oregon-public-employees-retirement-fund-takes-1-29-million-position-in-amedisys-inc-amed.html.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Featured Story: Outstanding Shares, Buying and Selling Stocks

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply